FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2742141246> ?p ?o ?g. }

• W2742141246 abstract "Although strategies incorporating immune checkpoint inhibition, e.g. PD-1/PD-L1 blockade, are achieving unprecedented successes and increasingly becoming incorporated into standard of care regimens for cancer patients, high rates of resistance still limit the potential efficacy. Therapeutic improvement requires a thorough understanding of the biological process of resistance. To date there have been few studies reporting mechanisms of resistance to PD-L1 blockade. We have explored the resistance mechanisms to functional PD-L1 loss in preclinical lung cancer models by using pharmacological and genetic approaches (PD-L1 blocking antibody treatment or CRISPR/Cas9-mediated deletion of PD-L1 on tumor cells). The molecular and immune profiles of the tumor microenvironment were evaluated in mutant K-ras/p53 (KP) GEM lung cancer models and multiple immunocompetent syngeneic models (both KP and Lewis lung cancer). Additionally, to determine the applicability of the results to patients with lung cancer, we analyzed 259 patient tumor specimens with IHC staining and evaluated the immune markers in TCGA datasets (adenocarcinoma and squamous) and the MD Anderson PROSPECT dataset. We observed that lung tumors gained resistance to anti-PD-L1 antibody treatment over time, and that the up-regulation of CD38 on tumor cells accounted for the treatment resistance. We also observed the same resistance mechanism caused by CD38 up-regulation in PD-L1 KO mice bearing PD-L1 KO Lewis lung tumors generated with the CRISPR/Cas9 system. Manipulation of CD38 on a panel of lung cancer cell lines, demonstrated that CD38 inhibits CD8+ T cell proliferation, antitumor cytokine secretion, and tumor cell killing capability in vitro and in vivo. Furthermore, to test whether CD38 blockade might be therapeutically efficacious to counter anti-PD-L1 resistance, we applied the combination therapy of anti-CD38 and anti-PD-L1 in lung cancer animal models and demonstrated dramatic therapeutic benefit on primary tumor growth and metastasis. Bioinformatic analyses of the patient tumor databases revealed a strong correlation between CD38 expression and an immune suppressive inflammatory signature. Finally, in 259 lung cancer specimens, 18.5% of cases exhibited positive staining for CD38 on tumor cells. Based upon our studies, we conclude that the up-regulation of CD38 on tumor cells is a major mechanism of resistance to anti-PD-L1 therapy, and that CD38 is a novel immune checkpoint that inhibits CD8+ T cell function. The blockade of CD38 and PD-L1 is a rational combination to prevent immune resistance and increase the response rate for lung cancer patients. Citation Format: Limo Chen, Lixia Diao, Yongbin Yang, Xiaohui Yi, Jaime Rodriguez, Youhong Fan, Leticia Rodriguez, Jared Fradette, Christin Ungewiss, Jonothan Roybal, Jingfen Zhu, Jing Wang, Lauren Byers, Stephen Ullrich, Ignacio Wistuba, John Heymach, Xiao-Feng Qin, Don Gibbons. CD38 blockade overcomes the immune resistance to anti-PD-L1 therapy by boosting CD8 T cell response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 567. doi:10.1158/1538-7445.AM2017-567" @default.
• W2742141246 created "2017-08-08" @default.
• W2742141246 creator A5006992463 @default.
• W2742141246 creator A5007057062 @default.
• W2742141246 creator A5009004976 @default.
• W2742141246 creator A5010884206 @default.
• W2742141246 creator A5011438589 @default.
• W2742141246 creator A5016679728 @default.
• W2742141246 creator A5031427523 @default.
• W2742141246 creator A5034595514 @default.
• W2742141246 creator A5037677450 @default.
• W2742141246 creator A5042586171 @default.
• W2742141246 creator A5044361780 @default.
• W2742141246 creator A5048380048 @default.
• W2742141246 creator A5048440738 @default.
• W2742141246 creator A5067291177 @default.
• W2742141246 creator A5067755477 @default.
• W2742141246 creator A5075320245 @default.
• W2742141246 creator A5078178224 @default.
• W2742141246 creator A5091557245 @default.
• W2742141246 date "2017-07-01" @default.
• W2742141246 modified "2023-09-24" @default.
• W2742141246 title "Abstract 567: CD38 blockade overcomes the immune resistance to anti-PD-L1 therapy by boosting CD8 T cell response" @default.
• W2742141246 doi "https://doi.org/10.1158/1538-7445.am2017-567" @default.
• W2742141246 hasPublicationYear "2017" @default.
• W2742141246 type Work @default.
• W2742141246 sameAs 2742141246 @default.
• W2742141246 citedByCount "0" @default.
• W2742141246 crossrefType "proceedings-article" @default.
• W2742141246 hasAuthorship W2742141246A5006992463 @default.
• W2742141246 hasAuthorship W2742141246A5007057062 @default.
• W2742141246 hasAuthorship W2742141246A5009004976 @default.
• W2742141246 hasAuthorship W2742141246A5010884206 @default.
• W2742141246 hasAuthorship W2742141246A5011438589 @default.
• W2742141246 hasAuthorship W2742141246A5016679728 @default.
• W2742141246 hasAuthorship W2742141246A5031427523 @default.
• W2742141246 hasAuthorship W2742141246A5034595514 @default.
• W2742141246 hasAuthorship W2742141246A5037677450 @default.
• W2742141246 hasAuthorship W2742141246A5042586171 @default.
• W2742141246 hasAuthorship W2742141246A5044361780 @default.
• W2742141246 hasAuthorship W2742141246A5048380048 @default.
• W2742141246 hasAuthorship W2742141246A5048440738 @default.
• W2742141246 hasAuthorship W2742141246A5067291177 @default.
• W2742141246 hasAuthorship W2742141246A5067755477 @default.
• W2742141246 hasAuthorship W2742141246A5075320245 @default.
• W2742141246 hasAuthorship W2742141246A5078178224 @default.
• W2742141246 hasAuthorship W2742141246A5091557245 @default.
• W2742141246 hasConcept C121608353 @default.
• W2742141246 hasConcept C126322002 @default.
• W2742141246 hasConcept C143998085 @default.
• W2742141246 hasConcept C154317977 @default.
• W2742141246 hasConcept C167672396 @default.
• W2742141246 hasConcept C170493617 @default.
• W2742141246 hasConcept C202751555 @default.
• W2742141246 hasConcept C203014093 @default.
• W2742141246 hasConcept C2776107976 @default.
• W2742141246 hasConcept C2776256026 @default.
• W2742141246 hasConcept C2777701055 @default.
• W2742141246 hasConcept C2778468042 @default.
• W2742141246 hasConcept C2780851360 @default.
• W2742141246 hasConcept C2781053074 @default.
• W2742141246 hasConcept C502942594 @default.
• W2742141246 hasConcept C55493867 @default.
• W2742141246 hasConcept C71924100 @default.
• W2742141246 hasConcept C86803240 @default.
• W2742141246 hasConcept C8891405 @default.
• W2742141246 hasConceptScore W2742141246C121608353 @default.
• W2742141246 hasConceptScore W2742141246C126322002 @default.
• W2742141246 hasConceptScore W2742141246C143998085 @default.
• W2742141246 hasConceptScore W2742141246C154317977 @default.
• W2742141246 hasConceptScore W2742141246C167672396 @default.
• W2742141246 hasConceptScore W2742141246C170493617 @default.
• W2742141246 hasConceptScore W2742141246C202751555 @default.
• W2742141246 hasConceptScore W2742141246C203014093 @default.
• W2742141246 hasConceptScore W2742141246C2776107976 @default.
• W2742141246 hasConceptScore W2742141246C2776256026 @default.
• W2742141246 hasConceptScore W2742141246C2777701055 @default.
• W2742141246 hasConceptScore W2742141246C2778468042 @default.
• W2742141246 hasConceptScore W2742141246C2780851360 @default.
• W2742141246 hasConceptScore W2742141246C2781053074 @default.
• W2742141246 hasConceptScore W2742141246C502942594 @default.
• W2742141246 hasConceptScore W2742141246C55493867 @default.
• W2742141246 hasConceptScore W2742141246C71924100 @default.
• W2742141246 hasConceptScore W2742141246C86803240 @default.
• W2742141246 hasConceptScore W2742141246C8891405 @default.
• W2742141246 hasLocation W27421412461 @default.
• W2742141246 hasOpenAccess W2742141246 @default.
• W2742141246 hasPrimaryLocation W27421412461 @default.
• W2742141246 hasRelatedWork W1982531224 @default.
• W2742141246 hasRelatedWork W2484114506 @default.
• W2742141246 hasRelatedWork W2502514050 @default.
• W2742141246 hasRelatedWork W2503986998 @default.
• W2742141246 hasRelatedWork W2547305668 @default.
• W2742141246 hasRelatedWork W2547472645 @default.
• W2742141246 hasRelatedWork W2592596865 @default.
• W2742141246 hasRelatedWork W2594777667 @default.
• W2742141246 hasRelatedWork W2595182131 @default.
• W2742141246 hasRelatedWork W2623357046 @default.
• W2742141246 hasRelatedWork W2741858712 @default.
• W2742141246 hasRelatedWork W2911881300 @default.

• next